Position in EXEL
as of Jun 30, 2026
· filed Jul 13, 2026
Position Value
$453,888
+$138,089 QoQ
Shares Held
8,342
+13.3% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#15
of 47 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Wedmont Private Capital holds $14,119,633 across 15 Biotechnology names. EXEL ranks #7 (3.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
40,281 | $7,543,825 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3,524 | $1,750,476 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,310 | $816,837 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
2,474 | $596,159 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
15,587 | $551,623 | |
| 6 | IONS |
Ionis Pharmaceuticals Inc
|
6,723 | $533,066 | |
| 7 | EXEL |
Exelixis, Inc.
This page
|
8,342 | $453,888 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,413 | $425,355 |
All Filings in EXEL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $453,888 | 8,342 | Shares | Sole | 2026-07-13 | |
| 2026-03-31 | $315,799 | 7,363 | Shares | Sole | 2026-04-09 | |
| 2025-12-31 | $282,002 | 6,434 | Shares | Sole | 2026-01-08 | |
| No filing history on record for this holder in this stock. | ||||||